Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

Focusing on the complexity of PAH management, Ioana Preston, MD, discusses the importance of combination therapies, close monitoring, and provides insight on counseling patients through treatment.

EP: 1.Evolving Guidelines for PAH Treatment

EP: 2.New Therapeutic Frontiers in PAH

EP: 3.Addressing Unmet Needs and Disease Progression Challenges in Pulmonary Arterial Hypertension Management

EP: 4.Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension

EP: 5.Breaking Down the PAH Cost Burden

EP: 6.A New Era in PAH Treatment?

EP: 7.Clinical Evidence for Emerging PAH Therapies

EP: 8.Integrating New PAH Therapies into Clinical Practice

Now Viewing

EP: 9.Optimizing Complex Pulmonary Arterial Hypertension Care: Enhancing Adherence and Outcomes

EP: 10.FDA Approves Sotatercept for Pulmonary Arterial Hypertension

EP: 11.Overcoming Barriers to Better Patient Outcomes in PAH

EP: 12.Advancing Pulmonary Arterial Hypertension Care: Overcoming Challenges in Special Populations and Exploring Innovative Approaches

EP: 13.Optimizing PAH Care Delivery for Better Outcomes

EP: 14.Addressing Unmet Needs in the PAH Landscape

Video content above is prompted by the following question:

• How does the complexity of pulmonary arterial hypertension (PAH) management, including the need for combination therapies and close monitoring, impact patient adherence and disease control?

Related Videos

Related Content

Advertisement

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

May 30th 2025

Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

Hayden E. Klein

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.

May 28th 2025

Suboptimal Care for PAH Persists Among Women

Maggie L. Shaw

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were viewed as dismissive because of the patient’s sex.

May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

May 6th 2025

18MWT Contributes Valuable Feedback in Setting of PAH

Maggie L. Shaw

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.

April 28th 2025

PH, PAH Prevalence Higher in Medicaid, With Racial, Ethnic Disparities

Laura Joszt, MA

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.

Related Content

Advertisement

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

May 30th 2025

Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

Hayden E. Klein

The pulmonary arterial hypertension (PAH) drug preserved its safety profile at 2.5 years of treatment and continued to reduce mortality compared with placebo.

May 28th 2025

Suboptimal Care for PAH Persists Among Women

Maggie L. Shaw

Findings from surveys of women with pulmonary arterial hypertension (PAH) include that 20% of health care providers were viewed as dismissive because of the patient’s sex.

May 15th 2025

Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

Maggie L. Shaw

Cardiac output and stroke volume as measured by impedance cardiography may hold potential to predict clinical deterioration from pulmonary arterial hypertension (PAH).

May 6th 2025

18MWT Contributes Valuable Feedback in Setting of PAH

Maggie L. Shaw

The 18-meter walk test (18MWT) effectively evaluates disease severity and predicts clinical outcomes in pulmonary arterial hypertension (PAH), enhancing traditional assessment methods.

April 28th 2025

PH, PAH Prevalence Higher in Medicaid, With Racial, Ethnic Disparities

Laura Joszt, MA

Medicaid beneficiaries face higher rates of pulmonary hypertension, with significant economic burdens and racial disparities in prevalence and costs.